Cardiovascular Systems, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended December 31, 2016; Provides Earnings Guidance for the Third Quarter Ending March 31, 2017
For the six months, the company reported net revenue was $99.843 million against $85.263 million a year ago. Loss from operations was $0.785 million against loss of $28.379 million a year ago. Loss before income taxes was $0.767 million against loss of $28.378 million a year ago. Net loss was $0.815 million against loss of $28.424 million a year ago. Diluted loss per share was $0.03 against loss of $0.88 a year ago. Adjusted EBITDA was $7.204 million against loss of $19.239 million a year ago.
For the third quarter ending March 31, 2017, the company anticipates revenue in a range of $50.5 million to $51.5 million; gross profit as a percentage of revenues of about 81%; net loss in the range of $1.2 million to $1.8 million, or loss per common share ranging from $0.04 to $0.06, assuming approximately 32.6 million average shares outstanding; and positive adjusted EBITDA.